More Videos
- Pfizer's Statin Study: What An Email Response!
- Is Merck A Drug Bellwether?
- Pfizer's Statin Study: What A Coincidence!
- Sam Waksal: "Moving On Up" To The East Side
- Another "Short" Story About Pfizer & Dendreon
- Predictions: 9 For '09 In Pharma
- Johnson & Johnson Is Latest FDA Casualty
- Genentech: Roche Says One Thing, Investors Say Another
- Schering-Plough: The Reviews Are In
- Pharma Updates And What You Need To Know
- Pfizer's Statin Study: What An Email Response!
- PGA Spokesman: Sponsors Believe In Us For Long Term
- Kilduff: Expect Rebound In Oil Prices Early 2009
- How to Move Forward After a Layoff, Part 2
- Jobs Numbers: Breakdown by Sector
- Congress And Automakers: Long And Difficult "Marriage" Ahead
- Great Companies Come at Fair Prices
- Yoshikami: Investing & the Obama Presidency
- Wall of Shame: Fortress Investment's Wes Edens
- Plunging Yields Take Shine Off Treasurys
- Job Losses Hit 533,000 Last Month, Worst in 34 Years
- Citigroup Sells German Arm for $6.7 Billion
- Charts Predict S&P Festive Rally Above 1,000
- BMW's Global Sales Plunge by a Quarter in Nov.
- What the Pros Say: S&P May Fall to 700
- Bleak Jobs Data Forecasts Add to Automakers' Woes
- Euro Shares Sink after Grim US Jobs Data
- European Stocks to Open Sharply Lower
Text Size 
 |
CNBC.com |
In a bear market, shares of ELN [ELN
Loading...
()
]are up a whopping 37 percent over the past month since it and partner Wyeth [WYE
Loading...
()
]announced the basic results of the mid-stage test on their promising Alzheimer's drug. Researchers will get into the nitty-gritty data at the big Alzheimer's conference the end of this month in Chicago. We will be there and yes, dear Elanians, we have requested a live interview with CEO Kelly Martin, but have not received an answer yet.
Anyway, because of the recent run-up in the stock, the Cowen analysts say, "The current valuation implies bap (shorthand for the name of the Alzheimer's drug) sales of $7-$8 billion in 2015. This ultimately may prove conservative, but with minimal topline (the basic clinical trial data released so far) Phase 2 results in-hand and Phase 3 data 2-plus years away, we believe ELN shares have limited near-term upside potential. Therefore, we are initiating coverage of Elan with a Neutral investment rating." Their estimate of peak bap sales actually goes as high as $12 billion in the 2015-2020 timeframe. That's Lipitor money.
related content |
Cowen says bap could be a game-changer and the first disease modifying treatment for Alzheimer's, but that it's "too early to draw that conclusion based on the very limited" data available. The analysts believe the detailed test results that will come out in Chicago on Tuesday, July 29th, will be stock-moving. If everything continues to look good, Cowen says WYE and ELN could file for Food and Drug Administration approval of bap as early as December of 2009 and get the green light and launch the drug, under a best-case scenario, by the second half of 2010.
Normally I only print disclosures when they exist, but since this is a big coverage initiation I'm making an exception to my own rule to mention that there are no disclosures listed in the Cowen note.
P.S. My apologies to UBS analyst Roopesh Patel for misspelling his name in yesterday's post about his stock-moving call on Merck[MRK
Loading...
()
].
Questions? Comments?
Del.icio.us
Digg It
Data is a real-time snapshot *Data is delayed at least 15 minutes